Literature DB >> 1539467

The mucosal immune system: from fundamental concepts to vaccine development.

J R McGhee1, J Mestecky, M T Dertzbaugh, J H Eldridge, M Hirasawa, H Kiyono.   

Abstract

Recent studies in experimental animals and humans have shown that the mucosal immune system, which is characterized by secretory IgA (S-IgA) antibodies as the major humoral defence factor, contains specialized lymphoid tissues where antigens are encountered from the environment, are taken up and induce B- and T-cell responses. This event is followed by an exodus of specific lymphocytes, which home to various effector sites such as the lamina propria regions and glands. These responses are regulated by T cells and cytokines and lead to plasma cell differentiation and subsequent production of S-IgA antibodies in external secretions. This knowledge has led to practical approaches for vaccine construction and delivery into mucosal inductive sites in an effort to elicit host protection at mucosal surfaces where the infection actually occurs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539467     DOI: 10.1016/0264-410x(92)90021-b

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  183 in total

1.  Chlamydial colonization of multiple mucosae following infection by any mucosal route.

Authors:  L L Perry; S Hughes
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.

Authors:  F Velge-Roussel; P Marcelo; A C Lepage; D Buzoni-Gatel; D T Bout
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

Authors:  B Baras; M A Benoit; L Dupré; O Poulain-Godefroy; A M Schacht; A Capron; J Gillard; G Riveau
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Route and type of nutrition influence mucosal immunity to bacterial pneumonia.

Authors:  B K King; K A Kudsk; J Li; Y Wu; K B Renegar
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

Review 5.  The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.

Authors:  G Dougan; M Ghaem-Maghami; D Pickard; G Frankel; G Douce; S Clare; S Dunstan; C Simmons
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

Review 6.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Considerations for use of acupuncture as supplemental therapy for patients with allergic asthma.

Authors:  Yong-Qing Yang; Han-Ping Chen; Yu Wang; Lei-Miao Yin; Yu-Dong Xu; Jun Ran
Journal:  Clin Rev Allergy Immunol       Date:  2013-06       Impact factor: 8.667

8.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

Review 9.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

10.  Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

Authors:  J U Igietseme; I M Uriri; S N Kumar; G A Ananaba; O O Ojior; I A Momodu; D H Candal; C M Black
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.